Autologous hematopoietic stem cell transplantation in elderly patients (≥70years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study
| Autor: | E, Hermet, A, Cabrespine, R, Guièze, A, Garnier, A, Tempescul, P, Lenain, R, Bouabdallah, J P, Vilque, J, Frayfer, D, Bordessoule, D, Sibon, M, Janvier, D, Caillot, P, Biron, L, Legros, B, Choufi, B, Drenou, N C, Gorin, K, Bilger, J, Tamburini, C, Soussain, S, Brechignac, J O, Bay, R, Guieze |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Melphalan Oncology medicine.medical_specialty medicine.medical_treatment Cell- and Tissue-Based Therapy Follicular lymphoma Hematopoietic stem cell transplantation Disease-Free Survival Autologous stem-cell transplantation immune system diseases hemic and lymphatic diseases Internal medicine Prevalence medicine Humans Societies Medical Aged Bone Marrow Transplantation Retrospective Studies Aged 80 and over business.industry Incidence Lymphoma Non-Hodgkin Hematopoietic Stem Cell Transplantation medicine.disease Surgery Non-Hodgkin's lymphoma Lymphoma Survival Rate Transplantation Female Mantle cell lymphoma France Geriatrics and Gerontology business Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Geriatric Oncology. 6:346-352 |
| ISSN: | 1879-4068 |
| DOI: | 10.1016/j.jgo.2015.04.005 |
| Popis: | Introduction Limited data is available on the feasibility of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) in elderly patients over 70years of age with non-Hodgkin's lymphoma (NHL). Materials and Methods In the setting of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) group, we retrospectively analyzed 81 consecutive patients with NHL over 70years of age who received AHSCT. Results The median age at AHSCT was 72.3years [70–80]. Patients' were diagnosed with diffuse large B-cell lymphoma (n=40), follicular lymphoma (n=16), mantle cell lymphoma (n=15), T-cell lymphoma (n=5), and other (n=5). Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) was 0 in 73% of patients. Main conditionings were BEAM (Carmustine-Etoposide-Cytarabine-Melphalan, n=61) and melphalan alone (n=14). Median delays to reach 0.5×10 9 /L neutrophils and 20×10 9 /L platelets were of 12 [9–76] days and 12 [0–143] days, respectively. One hundred day and one year cumulative incidence of NRM was 5.4% and 8.5%, respectively. The main cause of death remains relapse. Conclusion In conclusion, this study revealed that AHSCT seemed to be acceptable in patients over 70years of age with NHL. Patient age is not a limiting factor if clinical condition is adequate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect